Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER-2/neu Overexpressing Breast Tumor Xenografts

PURPOSE: We have shown that incomplete blockade of the Human Epidermal Growth Factor (HER) pathway is a mechanism of resistance to treatment with trastuzumab (T) in HER2-overexpressing tumor xenografts. We now investigate whether the addition of lapatinib (L), a dual HER1/2 kinase inhibitor, to T re...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Rimawi, Mothaffar F., Wiechmann, Lisa S., Wang, Yen-Chao, Huang, Catherine, Migliaccio, Ilenia, Wu, Meng-Fen, Gutierrez, Carolina, Hilsenbeck, Susan G., Arpino, Grazia, Massarweh, Suleiman, Ward, Robin, Soliz, Robert, Osborne, C. Kent, Schiff, Rachel
פורמט: Artigo
שפה:Inglês
יצא לאור: 2010
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3060302/
https://ncbi.nlm.nih.gov/pubmed/21138857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1905
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים